NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/07/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization1,694.74 mln
Earnings Date08/10/2026
EPS
8.53
Strong
P / E
3.17
Deeply undervalued
Piotroski F-Score
6
/ 9
Solid
Beneish M-Score
0.58
Highly suspicious
1-Year Forecast
25.51
Limited downside
Relative Strength
17
/ 100
Significantly lagging
Business Description
Lakefront Biotherapeutics NV is a Belgian biotechnology company, founded in 1999 and headquartered in Mechelen, that develops treatments for cancer and immune system diseases across the United States and Europe. The company has several drugs in clinical testing, including therapies for conditions such as lupus, lymphoma, and multiple myeloma, with some of its most advanced treatments produced directly at the point of patient care. It works in partnership with Gilead Sciences and was previously known as Galapagos NV before changing its name in May 2026.
